[go: up one dir, main page]

UY31231A1 - PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF A BENZISOXAZOLIC DERIVATIVE AGENT AND A REVERSIBLE INHIBITING AGENT OF CHOLINESTERASE ENZYME, INDICATED FOR THE CONTROL AND TREATMENT OF PSYCHOTIC DISORDERS AND DEMENCIES. - Google Patents

PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF A BENZISOXAZOLIC DERIVATIVE AGENT AND A REVERSIBLE INHIBITING AGENT OF CHOLINESTERASE ENZYME, INDICATED FOR THE CONTROL AND TREATMENT OF PSYCHOTIC DISORDERS AND DEMENCIES.

Info

Publication number
UY31231A1
UY31231A1 UY31231A UY31231A UY31231A1 UY 31231 A1 UY31231 A1 UY 31231A1 UY 31231 A UY31231 A UY 31231A UY 31231 A UY31231 A UY 31231A UY 31231 A1 UY31231 A1 UY 31231A1
Authority
UY
Uruguay
Prior art keywords
agent
indicated
treatment
pharmaceutical composition
control
Prior art date
Application number
UY31231A
Other languages
Spanish (es)
Inventor
Ochoa Victor Guillermo Alvarez
Murillo Josefina Santos
Armenta Maria Elena Garcia
Original Assignee
World Trade Imp Export Wtie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by World Trade Imp Export Wtie Ag filed Critical World Trade Imp Export Wtie Ag
Publication of UY31231A1 publication Critical patent/UY31231A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención esta relacionada con una composición farmacéutica compuesta por la combinación sinérgica de un agente derivado benzisoxazólico, como lo es el principio activo: Risperidona y un agente inhibidor reversible de colinesterasa, como lo es el principio activo: Donepezilo; los cuales se encuentran formulados en una sola unidad de dosificación para ser administrada por vía oral en forma de cápsula o tableta; misma que está indicada para el control y tratamiento de enfermedades tales como: trastornos psicóticos, como la esquizofrenia, demencia vascular, demencia del tipo de Alzheimer y otras enfermedades relacionadas.The present invention is related to a pharmaceutical composition composed of the synergistic combination of a benzisoxazole derivative agent, such as the active ingredient: Risperidone and a reversible cholinesterase inhibitor, such as the active ingredient: Donepezil; which are formulated in a single dosage unit to be administered orally in capsule or tablet form; It is indicated for the control and treatment of diseases such as: psychotic disorders, such as schizophrenia, vascular dementia, Alzheimer's type dementia and other related diseases.

UY31231A 2007-07-16 2008-07-16 PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF A BENZISOXAZOLIC DERIVATIVE AGENT AND A REVERSIBLE INHIBITING AGENT OF CHOLINESTERASE ENZYME, INDICATED FOR THE CONTROL AND TREATMENT OF PSYCHOTIC DISORDERS AND DEMENCIES. UY31231A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2007008642A MX2007008642A (en) 2007-07-16 2007-07-16 Pharmaceutical composition comprising the combination of a benzisoxazolic derived agent and a reversible inhibiting agent of the cholinesterase enzyme prescribed for the control and treatment of psychotic disorders and dementias.

Publications (1)

Publication Number Publication Date
UY31231A1 true UY31231A1 (en) 2009-01-05

Family

ID=40259824

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31231A UY31231A1 (en) 2007-07-16 2008-07-16 PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF A BENZISOXAZOLIC DERIVATIVE AGENT AND A REVERSIBLE INHIBITING AGENT OF CHOLINESTERASE ENZYME, INDICATED FOR THE CONTROL AND TREATMENT OF PSYCHOTIC DISORDERS AND DEMENCIES.

Country Status (4)

Country Link
AR (1) AR069538A1 (en)
MX (1) MX2007008642A (en)
UY (1) UY31231A1 (en)
WO (1) WO2009011560A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0103781A3 (en) * 1998-10-16 2003-09-29 Janssen Pharmaceutica Nv Pharmaceutical compositions comprising atypical antiphsychotic agent in combination with acetylcholinesterase inhibitor for improving cognition
WO2005065645A2 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Donepezil formulations

Also Published As

Publication number Publication date
MX2007008642A (en) 2009-02-25
WO2009011560A1 (en) 2009-01-22
AR069538A1 (en) 2010-02-03

Similar Documents

Publication Publication Date Title
ES2916649T1 (en) Compositions and uses for the treatment of multiple sclerosis
SV2010003491A (en) 2- ANILINOPURIN-8-ONAS AS INHIBITORS OF TTK / MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS
EA201690102A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING DIMETHYLFUMATE FOR INTRODUCTION TO LOW DAILY DOSE
AR066214A1 (en) DERIVATIVES OF PIRAZOLOPIRIMIDINAS AS INHIBITORS OF CYCLINE-DEPENDENT KINASES. PHARMACEUTICAL USES AND COMPOSITIONS
ECSP066990A (en) FORMULATIONS WITH CONTROLLED RELEASE OF ACTIVE PRINCIPLE CONTAINING VARDENAFILO
JP2015038135A5 (en)
AR085662A1 (en) METHODS AND COMPOSITIONS TO TREAT HYPERURICEMIA AND METABOLIC DISORDERS ASSOCIATED WITH HYPERURICEMIA
AR068745A1 (en) A COMPOSITION IN THE FORM OF ORAL PHARMACEUTICAL DOSAGE OF HIGH DOSAGE UNIT OF SODIUM MYCOPHENOLATE, METHOD FOR USING SUCH COMPOSITION AND ITS USES
BR112015029401A2 (en) pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of diseases
AR056824A1 (en) NERAMEXAN TABLET WITH MODIFIED LIBERATION MATRIX
CO6260085A2 (en) PHARMACEUTICAL COMPOSITION CONTAINING A SYNERGIC COMBINATION OF VENOTONICS AND VASOPROTECTORS
MX2019001596A (en) USE AND DOSAGE OF THERAPEUTIC AGENTS FOR ENDOMETRIOSIS.
AR107935A1 (en) USE OF COMPOUND 6- (4- (2,3-DIMETHYLPHENOXY) PIPERIDIN-1-IL) METHYL) PYRIMIDINE-2,4 (1H, 3H) -DIONA OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME TO PREPARE A MEDICINAL, COMBINATION AND COMPOSITION PHARMACEUTICAL UNDERSTANDING SUCH COMPOUND
UY30029A1 (en) DERIVATIVES OF PIPERIDINE, ITS PHARMACEUTICALLY ACCEPTABLE SALTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND APPLICATIONS
CO6270220A2 (en) PHARMACEUTICAL COMPOSITIONS UNDERSTANDING THE COMBINATION OF A NON-STEROID ANTIINFLAMOTORY AGENT AND AN INHIBITING AGENT OF THE XANTINO OXIDASE USEFUL FOR THE CONTROL AND TREATMENT OF THE DROP DROPPED ARTHRITIS AND RELATED DISEASES
AR088845A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING 7- (1H-IMIDAZOL-4-ILMETIL) -5,6,7,8-TETRAHYDRO-QUINOLINE FOR THE TREATMENT OF SKIN DISEASES AND AFFECTIONS
AR074246A1 (en) DERIVATIVES OF 1-AMINO-ALQUILCICLOHEXANO FOR THE TREATMENT OF SOIL DISORDERS
UY31231A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF A BENZISOXAZOLIC DERIVATIVE AGENT AND A REVERSIBLE INHIBITING AGENT OF CHOLINESTERASE ENZYME, INDICATED FOR THE CONTROL AND TREATMENT OF PSYCHOTIC DISORDERS AND DEMENCIES.
DOP2010000265A (en) ORAL GALENIC FORMULATION INCLUDING KETOROLACO AND VITAMINS OF COMPLEX B, IN WHICH VITAMIN B6 IS FOUND AN EXTERNAL LAYER SEPARATED FROM THE REST OF ACTIVE PRINCIPLES
UY31212A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF A BENZISOXAZOLIC DERIVATIVE AGENT AND A BENZODIAZEPINIC AGENT
BR112012020415A2 (en) pharmaceutical composition for the prevention or treatment of osteoarthritis
GT200900275A (en) SYNERGIC PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THE COMBINATION OF AN INHIBITOR OF ENZYME 5 A-REDUCTASE AND AN ANTAGONIST OF RECEIVERS 1 A-ANDRENÉRGICOS.
CO6241106A2 (en) PHARMACEUTICAL COMPOSITION UNDERSTANDING THE COMBINATION OF AN INHIBITING AGENT OF THE HMG-COA REDUCTASE ENZYME AND AN INHIBITING AGENT OF THE GASTROINTESTINAL ENZYME LIPASE
ECSP099733A (en) PHARMACEUTICAL COMPOSITION UNDERSTANDING THE COMBINATION OF THE CIPROFLOXACINE ANTIMICROBIAL AGENT AND THE ASCORBIC ACID ANTIOXIDANT AGENT FOR THE TREATMENT OF URINARY INFECTION
ECSP109996A (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF AN ANTIMICROBIAL AGENT AND A SELECTIVE INHIBITING AGENT OF THE ENCEPHALINASE ENZYME, INDICATED FOR THE CONTROL AND TREATMENT OF THE ACUTE BACTERIAL DIARRHEA

Legal Events

Date Code Title Description
104 Application deemed to be withdrawn (no substantive examination fee paid)

Effective date: 20171004